Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10752784 | 0.88 | GSK3B (0.50) | GSK3BHPGDSARL3MBTL1MAPT | |
| SCHEMBL20855621 | 0.85 | L3MBTL1 (0.51) | ARL3MBTL1MAPTUSP2ALDH1A1 | |
| SCHEMBL546183 | 0.84 | AR (0.50) | ARL3MBTL1MAPTALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL30468134 | 0.84 | AR (0.44) | ARL3MBTL1MAPTUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10984138 | 0.83 | AR (0.49) | ARL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL20855586 | 0.81 | AR (0.50) | ARL3MBTL1MAPTUSP2ALDH1A1 | |
| SCHEMBL30468153 | 0.81 | AR (0.50) | ARL3MBTL1MAPTUSP2ALDH1A1 | |
| SCHEMBL26388243 | 0.80 | GSK3B (0.45) | GSK3BARPTGDR2SLC6A9 | |
| SCHEMBL385459 | 0.80 | AR (0.49) | ARL3MBTL1MAPTALDH1A1MEN1 | |
| SCHEMBL477893 | 0.80 | AR (0.49) | ARL3MBTL1MAPTUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| CN-115698001-A | N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | GSK3B 3523/4885HPGDS 2401/4885AR 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.